Semmaphorin 3 A causes immune suppression by inducing cytoskeletal paralysis in tumour-specific CD8⁺ T cells.

Autor: Barnkob, Mike B., Michaels, Yale S., André, Violaine, Macklin, Philip S., Gileadi, Uzi, Valvo, Salvatore, Rei, Margarida, Kulicke, Corinna, Chen, Ji-Li, Jain, Vitul, Woodcock, Victoria K., Colin-York, Huw, Hadjinicolaou, Andreas V., Kong, Youxin, Mayya, Viveka, Mazet, Julie M., Mead, Gracie-Jennah, Bull, Joshua A., Rijal, Pramila, Pugh, Christopher W.

Publikováno v: Nature Communications; 4/12/2024, Vol. 15 Issue 1, p1-18, 18p

PemBla: A Phase 1 study of intravesical pembrolizumab in recurrent non‐muscle‐invasive bladder cancer.

Autor: Woodcock, Victoria K., Chen, Ji‐Li, Purshouse, Karin, Butcher, Chrissie, Collins, Linda, Haddon, Caroline, Verrall, Gillian, Elhussein, Leena, Roberts, Corran, Tarlton, Andrea, Rei, Margarida, Napolitani, Giorgio, Salio, Mariolina, Middleton, Mark R., Cerundolo, Vincenzo, Crew, Jeremy, Protheroe, Andrew S.

Publikováno v: BJUI Compass; May2023, Vol. 4 Issue 3, p322-330, 9p

A TCR/anti-CD3 bispecific fusion protein targeting gp100 potently activated anti-tumor immune responses in metastatic melanoma

Autor: Middleton, Mark R., McAlpine, Cheryl, Woodcock, Victoria K., Corrie, Pippa, Infante, Jeffry R., Steven, Neil Mathew, Evans, Thomas R Jeffry, Anthoney, Alan, Shoushtari, Alexander Noor, Hamid, Omid, Gupta, Avinash, Vardeu, Antonella, Leach, Emma, Naidoo, Revashnee, Stanhope, Sarah, Lewis, Sion, Hurst, Jacob, O’Kelly, Ita, Sznol, Mario

Publikováno v: Clin Cancer Res

PURPOSE: Tebentafusp is a first-in-class bispecific fusion protein designed to target gp100 (a melanoma-associated antigen) through a high affinity T cell receptor (TCR) binding domain, and an anti-CD3 T cell engaging domain which redirects T cells t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::3cd79fcc3541f956201ae1b81d927e61
https://europepmc.org/articles/PMC9210997/

A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424

Autor: Woodcock, Victoria K, Clive, Sally, Wilson, Richard H., Coyle, Vicky M, Stratford, Michael R L, Folkes, Lisa K, Eastell, Richard, Barton, Claire, Jones, Paul, Kazmi-Stokes, Shamim, Turner, Helen, Halford, Sarah, Harris, Adrian L, Middleton, Mark R

Publikováno v: Woodcock, V K, Clive, S, Wilson, R H, Coyle, V M, Stratford, M R L, Folkes, L K, Eastell, R, Barton, C, Jones, P, Kazmi-Stokes, S, Turner, H, Halford, S, Harris, A L & Middleton, M R 2018, ' A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424 ', British Journal of Cancer, vol. 118, pp. 770-776 . https://doi.org/10.1038/bjc.2017.484
British Journal of Cancer

Background: Src is involved in cancer invasion and metastasis. AZD0424, an oral inhibitor of Src and ABL1, has shown evidence of anti-tumour activity in pre-clinical studies. Methods: A phase Ia, dose escalation study was performed to assess the safe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::b9ecb37f1d088d8a64f336eb274e79b6
http://ora.ox.ac.uk/objects/uuid:

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.